(NASDAQ: LXRX) Lexicon Pharmaceuticals's forecast annual revenue growth rate of 7.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.11%.
Lexicon Pharmaceuticals's revenue in 2026 is $49,803,000.On average, 7 Wall Street analysts forecast LXRX's revenue for 2026 to be $13,890,792,512, with the lowest LXRX revenue forecast at $10,214,092,170, and the highest LXRX revenue forecast at $16,015,127,096. On average, 7 Wall Street analysts forecast LXRX's revenue for 2027 to be $8,812,980,389, with the lowest LXRX revenue forecast at $0, and the highest LXRX revenue forecast at $26,469,446,172.
In 2028, LXRX is forecast to generate $30,507,546,076 in revenue, with the lowest revenue forecast at $3,114,052,491 and the highest revenue forecast at $55,120,847,491.